MX2022012711A - Hidroxiureametil-acilfulveno para tratar el cáncer de cerebro o el cáncer del snc. - Google Patents

Hidroxiureametil-acilfulveno para tratar el cáncer de cerebro o el cáncer del snc.

Info

Publication number
MX2022012711A
MX2022012711A MX2022012711A MX2022012711A MX2022012711A MX 2022012711 A MX2022012711 A MX 2022012711A MX 2022012711 A MX2022012711 A MX 2022012711A MX 2022012711 A MX2022012711 A MX 2022012711A MX 2022012711 A MX2022012711 A MX 2022012711A
Authority
MX
Mexico
Prior art keywords
cancer
hydroxyureamethyl
acylfulvene
treating brain
cns
Prior art date
Application number
MX2022012711A
Other languages
English (en)
Inventor
Aditya Kulkarni
Kishor Bhatia
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of MX2022012711A publication Critical patent/MX2022012711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para tratar el cáncer de tumor encefálico mediante la administración de hidroxiureametil-acilfulveno. Algunas modalidades se refieren al tratamiento de glioblastoma mediante la administración de hidroxiureametil-acilfulveno. El método también incluye la caracterización del subtipo y la genética de los marcadores.
MX2022012711A 2020-04-10 2021-04-12 Hidroxiureametil-acilfulveno para tratar el cáncer de cerebro o el cáncer del snc. MX2022012711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063008359P 2020-04-10 2020-04-10
PCT/US2021/026907 WO2021207738A1 (en) 2020-04-10 2021-04-12 Hydroxyureamethyl-acylfulvene for treating brain cancer or cns cancer

Publications (1)

Publication Number Publication Date
MX2022012711A true MX2022012711A (es) 2023-01-16

Family

ID=78023527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012711A MX2022012711A (es) 2020-04-10 2021-04-12 Hidroxiureametil-acilfulveno para tratar el cáncer de cerebro o el cáncer del snc.

Country Status (10)

Country Link
US (1) US20230181499A1 (es)
EP (1) EP4132489A4 (es)
JP (1) JP2023521422A (es)
KR (1) KR20220167308A (es)
CN (1) CN115605191A (es)
AU (1) AU2021251277A1 (es)
BR (1) BR112022020595A2 (es)
CA (1) CA3175181A1 (es)
MX (1) MX2022012711A (es)
WO (1) WO2021207738A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4989648B2 (ja) * 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体
KR102305226B1 (ko) * 2013-03-15 2021-09-29 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
CN106458922A (zh) * 2014-04-10 2017-02-22 Af化学药品有限责任公司 亲和药物共轭物
US10076518B2 (en) * 2015-03-06 2018-09-18 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor

Also Published As

Publication number Publication date
CA3175181A1 (en) 2021-10-14
KR20220167308A (ko) 2022-12-20
JP2023521422A (ja) 2023-05-24
EP4132489A1 (en) 2023-02-15
EP4132489A4 (en) 2024-06-05
AU2021251277A1 (en) 2022-11-10
WO2021207738A1 (en) 2021-10-14
US20230181499A1 (en) 2023-06-15
CN115605191A (zh) 2023-01-13
BR112022020595A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
PH12016502354A1 (en) Pharmaceutical composition
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2023002076A (es) Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica.
MY194341A (en) Method of treating a brain tumor
EA201300741A1 (ru) СПОСОБ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ АНТАГОНИСТОМ ГОНАДОТРОПИН-ВЫСВОБОЖДАЮЩЕГО ГОРМОНА (GnRH) ДЕГАРЕЛИКСОМ
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2021010916A (es) Inhibidores rad51.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
ZA201907225B (en) Treatment of her2 positive cancers
PH12019500177A1 (en) Treatment and prevention of sleep disorders
MX2020001727A (es) Terapia de combinacion.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2023008193A (es) Procedimientos para tratar el cáncer.
EA202092540A1 (ru) Комбинации для лечения рака
MX2021002006A (es) Tratamiento del cancer de mama triple negativo con inhibicion dirigida del factor de crecimiento transformante beta (tgf-b).
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
MX2022012711A (es) Hidroxiureametil-acilfulveno para tratar el cáncer de cerebro o el cáncer del snc.